Drug candidate for DME treatment to begin toxicology studies

THR-149, a plasma kallikrein inhibitor for the potential treatment of diabetic macular edema, has reached a milestone in its development and will start pivotal toxicology studies, according to a press release from ThromboGenics.This is the final step for the bicyclic peptide candidate (Bicycle, Bicycle Therapeutics) before beginning clinical development, which is expected in early 2018, the release said.